

### This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Pulmonary disease</b>				
Pulmonary fibrosis	NADPH oxidase 4 (NOX4)	<p>Mouse studies suggest inhibiting NOX4 could help treat age-related lung fibrosis. In aged mice with chemically induced pulmonary fibrosis, siRNA against <i>Nox4</i> or pharmacological inhibition with the small molecule GKT137831 increased fibrosis resolution and the recovery of body weight compared with control siRNA or no inhibition. Next steps include conducting further studies of GKT137831 and identifying additional NOX4 inhibitors to treat fibrosis.</p> <p>Genkyotex S.A.'s dual NOX1 and NOX4 inhibitor, GKT137831, is in Phase II testing to treat diabetic nephropathy and preclinical development for liver and pulmonary fibrosis.</p> <p><b>SciBX 7(18); doi:10.1038/scibx.2014.533</b> Published online May 8, 2014</p>	Unpatented; licensing status not applicable	<p>Hecker, L. <i>et al. Sci. Transl. Med.</i>; published online April 9, 2014; doi:10.1126/scitranslmed.3008182</p> <p><b>Contact:</b> Victor J. Thannickal, The University of Alabama at Birmingham, Birmingham, Ala. e-mail: <a href="mailto:vjthan@uab.edu">vjthan@uab.edu</a></p> <p><b>Contact:</b> Louise Hecker, same affiliation as above e-mail: <a href="mailto:lhecker@uab.edu">lhecker@uab.edu</a></p>